Looking for a new broker?
Elevation Oncology, Inc. stock is up 20.91% since 30 days ago. The next earnings date is Mar 7, 2024. The company has had below-average volume in the last 30 days. Its seasonality going into this month shows a chance of a red month, as 37.5% of the previous 12 December’s closed higher than November. 100% of analysts rate it a buy.
Elevation Oncology focuses on developing therapeutics for the treatment of cancer in genomically defined patient populations in the United States. The company's lead program is the seribantumab, an anti-HER3 monoclonal antibody that is in Phase II CRESTONE trial.
